Drug Information

Drug (ID: DG00322) and It's Reported Resistant Information

Name	Carboxyamidotriazole orotate
Indication	In total 1 Indication(s) Brain cancer [ICD-11: 2A00] Phase 2 [1]
Structure
Drug Resistance Disease(s)	Disease(s) with Clinically Reported Resistance for This Drug (1 diseases) Brain cancer [ICD-11: 2A00] [1]
Target	Interleukin-2 (IL2)	IL2_HUMAN	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	C22H16Cl3N7O6
IsoSMILES	C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2Cl)CN3C(=C(N=N3)C(=O)N)N)Cl)Cl.C1=C(NC(=O)NC1=O)C(=O)O
InChI	1S/C17H12Cl3N5O2.C5H4N2O4/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25;8-3-1-2(4(9)10)6-5(11)7-3/h1-6H,7,21H2,(H2,22,27);1H,(H,9,10)(H2,6,7,8,11)
InChIKey	MNWOBDDXRRBONM-UHFFFAOYSA-N
PubChem CID	11599548
TTD Drug ID	D00DAE

Type(s) of Resistant Mechanism of This Drug

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Brain cancer [ICD-11: 2A00]

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)		Click to Show/Hide
Key Molecule: Epidermal growth factor receptor/Protein Mdm4 (EGFR/MDM4)			[1]
Molecule Alteration	Structural mutation	Structural variation	Molecule Info
Resistant Disease	Glioblastoma [ICD-11: 2A00.02]		Disease Info
Experimental Note	Identified from the Human Clinical Data
Cell Pathway Regulation	PI3K signaling pathway	Activation	hsa04151
In Vivo Model	A retrospective survey in conducting clinical studies		Homo sapiens
Experiment for Molecule Alteration	FISH assay; Whole-exome sequencing assay; Exome sequencing assay
Experiment for Drug Resistance	Magnetic resonance imaging assay
Mechanism Description	Indeed, EGFR and MDM4 FISH analysis of the patient-derived primary GBM cells from the second recurrence showed the presence of DMs, which are known to be resistant to targeted chemotherapies as previously reported.

References

Ref 1	Longitudinal analysis of treatment-induced genomic alterations in gliomas. Genome Med. 2017 Feb 2;9(1):12. doi: 10.1186/s13073-017-0401-9.